Company news
Sangamo Therapeutics, Inc. news in 2023
Sangamo Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.
Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results
October 31, 2023
Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
October 24, 2023
Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
October 23, 2023
Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit
September 19, 2023
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results
August 7, 2023
Sangamo Therapeutics Announces Second Quarter 2023 Conference Call and Webcast
July 31, 2023
Sangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing
July 19, 2023
Sangamo Therapeutics Announces Research Evaluation and Option Agreement With Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered Capsids
July 16, 2023
Sangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion Disease
June 28, 2023
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for Isaralgagene Civaparvovec for the Treatment of Fabry Disease
May 21, 2023
Sangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer
May 15, 2023
Sangamo Therapeutics to Present Pre-clinical Data From Its Genomic Engineering Platform at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
May 1, 2023
Sangamo Therapeutics Announces Strategic Update and Reports Preliminary First Quarter 2023 Financial Results
April 25, 2023
Sangamo Therapeutics Announces First Quarter 2023 Conference Call and Webcast
April 18, 2023
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results
February 21, 2023
Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease
February 21, 2023
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast
February 20, 2023
Calls in 2023
- Sangamo Therapeutics (NASDAQ:SGMO) Q3 2023 Earnings Call
Nov 2, 2023
Transcript - Sangamo Therapeutics (NASDAQ:SGMO) Q2 2023 Earnings Call
Aug 8, 2023
Transcript - Sangamo Therapeutics (NASDAQ:SGMO) Q1 2023 Earnings Call
Apr 27, 2023
Transcript - Sangamo Therapeutics (NASDAQ:SGMO) Q4 2022 Earnings Call
Feb 22, 2023
Transcript
Decks in 2023
- 65th Annual Meeting and Exposition of the American Society of Hematology (ASH) 2023
Conference · 14 slides · Dec 13, 2023